(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.94%) $83.06
(-1.16%) $1.619
(-0.35%) $2 339.10
(0.52%) $27.40
(0.53%) $927.00
(-0.13%) $0.934
(-0.07%) $11.02
(-0.19%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials...
Stats | |
---|---|
Dagens volum | 5.77M |
Gjennomsnittsvolum | 3.05M |
Markedsverdi | 15.24B |
EPS | HKD0 ( 2023-08-10 ) |
Last Dividend | HKD0.140 ( 2023-06-09 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 8.06 |
ATR14 | HKD0.00300 (0.07%) |
Volum Korrelasjon
China Grand Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
China Grand Korrelasjon - Valuta/Råvare
China Grand Økonomi
Annual | 2023 |
Omsetning: | HKD10.53B |
Bruttogevinst: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2023 |
Omsetning: | HKD10.53B |
Bruttogevinst: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2022 |
Omsetning: | HKD9.56B |
Bruttogevinst: | HKD5.95B (62.24 %) |
EPS: | HKD0.590 |
FY | 2021 |
Omsetning: | HKD8.60B |
Bruttogevinst: | HKD5.25B (61.03 %) |
EPS: | HKD0.677 |
Financial Reports:
No articles found.
China Grand Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0860 | 2019-06-12 |
Last Dividend | HKD0.140 | 2023-06-09 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | HKD0.542 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.09 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.46 | |
Div. Directional Score | 8.46 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2886.HK | Ex Dividend Junior | 2023-05-19 | Annually | 0 | 0.00% | |
1503.HK | Ex Dividend Junior | 2023-09-13 | Semi-Annually | 0 | 0.00% | |
0553.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
8092.HK | Ex Dividend Junior | 2023-08-14 | Sporadic | 0 | 0.00% | |
2005.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
1083.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
0158.HK | Ex Dividend Junior | 2023-06-15 | Semi-Annually | 0 | 0.00% | |
3692.HK | Ex Dividend Knight | 2023-09-15 | Semi-Annually | 0 | 0.00% | |
1651.HK | Ex Dividend Knight | 2023-08-22 | Semi-Annually | 0 | 0.00% | |
0696.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.179 | 1.500 | 6.43 | 9.64 | [0 - 0.5] |
returnOnAssetsTTM | 0.0835 | 1.200 | 7.22 | 8.66 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.264 | -1.000 | 7.36 | -7.36 | [0 - 1] |
currentRatioTTM | 1.224 | 0.800 | 8.88 | 7.10 | [1 - 3] |
quickRatioTTM | 0.982 | 0.800 | 8.93 | 7.14 | [0.8 - 2.5] |
cashRatioTTM | 0.239 | 1.500 | 9.78 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.148 | -1.500 | 7.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 13.26 | 1.000 | 6.20 | 6.20 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.181 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.116 | 2.00 | 9.94 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.221 | -1.500 | 9.12 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.620 | 1.000 | 3.01 | 3.01 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.258 | 1.000 | 6.83 | 6.83 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.190 | 1.000 | -0.0542 | -0.0542 | [0.2 - 2] |
assetTurnoverTTM | 0.468 | 0.800 | -0.216 | -0.172 | [0.5 - 2] |
Total Score | 11.45 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.06 | 1.000 | 9.29 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.81 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.116 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.24 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.181 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.264 | 1.500 | 7.36 | -7.36 | [0 - 1] |
pegRatioTTM | 0.131 | 1.500 | -2.46 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0604 | 1.000 | -0.990 | 0 | [0.1 - 0.5] |
Total Score | 5.46 |
China Grand
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.